Digital Spatial Profiling Demonstrates Profiling of Proteins and 1,000+ mRNAs Across Multiple Regions from FFPE Tissue Sections using Next Generation Sequencing Readout
First Customer Data Using Hyb & Seq Single Molecule Sequencing Demonstrates
Potential Utility in Oncology and Infectious Disease
“Over the last year we’ve made tremendous progress in advancing our pipeline of new technology platforms, and we’re proud of what our innovative teams have accomplished,” said
Digital Spatial Profiling
In two new studies presented at AGBT,
"By opening the DSP platform for readout on either nCounter system or NGS, we can offer almost every genomics lab in the world a clear and simple path to enter rapidly growing fields of spatial genomics and single cell biology,” stated
In a poster titled Spatially Resolved, Highly Multiplexed RNA and Protein Expression using NGS Readout of Digital Spatial Profiling Microscopy, slide-mounted FFPE lymphoid tissue samples were processed on NanoString’s DSP instrument, and were read out using Illumina’s miSeq® platform, simultaneously profiling 30 proteins and 20 mRNAs in each of 96 regions spanning the biopsy.
In a separate poster titled Spatially resolved in situ transcriptome analysis of FFPE tissues enabled by coupling Digital Spatial Profiling with an NGS readout, slide-mounted FFPE tumor biopsies processed on the DSP instrument were read out using NanoString’s Hyb & Seq platform, simultaneously profiling more than 1,000 unique transcripts in small regions of a FFPE biopsy, allowing researchers to map how the activation states of critical pathways differ across the morphology of the tumor.
The DSP instrument is currently intended for research use only and is not for use in diagnostic procedures.
Hyb & Seq
NanoString’s proprietary Hyb & Seq chemistry is designed to enable a workflow that is simpler and faster than current sequencing methods due to the absence of library preparation, enzymes and amplification. Hyb & Seq’s simple workflow and compatibility with a variety of sample types offer the potential for an ideal sample-to-answer solution for clinical sequencing. This unique chemistry also provides both short and long read capability simultaneously, as well as the ability to sequence both DNA and RNA in parallel. Previously,
In two new studies presented at the AGBT, Hyb & Seq data will be presented for the first time by external collaborators. These studies demonstrate the potential utility of Hyb & Seq for clinical sequencing in the fields of infectious disease and oncology.
In an oral presentation titled Simultaneous mutation detection, copy number measurement, and digital gene expression profiling of high-grade serous ovarian cancer FFPE samples using Hyb & Seq targeted sequencing technology, collaborators from
In a lunch workshop, Dr.
“Hyb & Seq is a new generation of sequencing chemistry offering high accuracy, flexibility, and simplicity that could enable a wide range of clinical applications in which rapid sample-to-answer capability is important,” stated
Hyb & Seq technology is currently for research use only and is not for use in diagnostic procedures.
Integrated Interrogation of Oncogenic Signaling Pathways, Immunology, and Heterogeneity in Cancer
|Michael A. Davies, MD, Ph.D. Associate Professor and Deputy Chairman, Department of Translational Molecular Pathology University of Texas MD Anderson Cancer Center|
Rapid and Accurate Cross-kingdom Human Pathogen Identification and Detection using Hyb & SeqTM Technology
|Christopher Mason, Ph.D. Institute for Computational Biomedicine Weill Cornell Medical College Department of Physiology and Biophysics|
|Program Moderator: Joseph M. Beechem, Ph.D., senior vice president of R&D, NanoString Technologies|
Presentations and posters include:
Title: Spatially resolved in situ transcriptome analysis of FFPE tissues enabled by coupling Digital Spatial Profiling Microscopy with an NGS readout
Poster #: 215
Title: Spatially resolved, highly multiplexed RNA and Protein expression using NGS readout of Digital Spatial Profiling Microscopy
Poster #: 417
Title: Rapid and accurate cross-kingdom human pathogen identification and detection using Hyb & Seq technology
Poster #: 217
Title: Simultaneous mutation detection, copy number measurement, and digital gene expression profiling of high-grade serous ovarian cancer FFPE samples using Hyb & SeqTM targeted sequencing technology
About NanoString Technologies, Inc.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the performance and attributes of Digital Spatial Profiling and Hyb & Seq chemistry, including potential clinical utility, the commercial availability of such products and the expectations for those products to contribute to future revenue growth in our business. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in our filings with the
Vice President, Investor Relations & Corporate Communications
Source: NanoString Technologies, Inc.